ArticlePharmaceutical research2008
Increased intestinal delivery of viable Saccharomyces boulardii by encapsulation in microspheres.
Article in Pharmaceutical research, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 85 citations in OpenAlex.
- Encapsulation of Saccharomyces spp. for Use as Probiotic in Food and Feed: Systematic Review and Meta-analysis.Probiotics and antimicrobial proteins · 2024Pooled it
- From Yeast Probiotics to Postbiotics: A Continuum Model and Yeast-Specific Functional Perspective.Cells · 2026Review
- Delivery of Probiotic-Loaded Microcapsules in the Gastrointestinal Tract: A Review.Probiotics and antimicrobial proteins · 2025Review
- Advances in Yeast Probiotic Production and Formulation for Preventative Health.Microorganisms · 2024Review
- Article
- Article
- Biopolymer encapsulation for improved probiotic delivery: Advancements and challenges.AIMS microbiology · 2024Review
- Evaluation of the impact of polypeptide-p on diabetic rats upon its cloning, expression, and secretion in Saccharomyces boulardii.Archives of microbiology · 2023Article
- Microencapsulation and sonication: A multiple physical approach to attenuate the probioticHeliyon · 2023Article
- Probiotic Encapsulation: Bead Design Improves Bacterial Performance during In Vitro Digestion.Polymers · 2023Article
- Article
- Review
- Microencapsulation ofFoods (Basel, Switzerland) · 2020Article
- The Use of Probiotic-Loaded Single- and Double-Layered Microcapsules in Cake Production.Probiotics and antimicrobial proteins · 2019Article
- Saccharomyces cerevisiae (Baker's Yeast) as an Interfering RNA Expression and Delivery System.Current drug targets · 2019Review
- Microencapsulation of Saccharomyces cerevisiae and its evaluation to protect in simulated gastric conditions.Iranian journal of microbiology · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeAlthough probiotics are of a major potential therapeutic interest, their efficacy is usually limited by poor bioavailability of viable microorganisms on site. The aim of this study was to protect the probiotic Saccharomyces boulardii from degradation in order to ensure a greater number of viable yeast in the colon.
methodsAlginate microspheres coated with or not with chitosan were used to encapsulate the yeast by an extrusion method. The efficiency of encapsulation was assessed both in vitro and in vivo.
resultsIn vitro, less than 1% of the non-encapsulated probiotic survived after 120 min at pH 1.1, whereas the majority of encapsulated yeast cells remained entrapped within both types of microspheres. Further exposure to a pH 6.8 allowed the release of about 35% of viable yeasts. In vivo, the percentage of viable yeast excreted over 96 h after a single oral dose of 2 x 10(8) cfu/100 g in rats was 2.5% for nonencapsulated yeast and reached 13.3 and 9.0% of the dose administered for the uncoated and chitosan-coated microspheres, respectively.
conclusionsGiven the dose-dependent efficacy of S. boulardii and the efficiency of microencapsulation in protecting the yeast from degradation, alginate microspheres could be of great interest in therapeutic applications of the yeast.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.